时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Frailty is common in chronic kidney disease (CKD) and is independently associated with disability and mortality. However, evidence on the optimal treatment of frail adults with CKD remains limited. Consequently, regulators have encouraged routine assessment of frailty and the reporting of outcomes stratified by frailty in clinical studies. In this narrative review, we found that several recent clinical trials of disease-modifying therapies for CKD evaluated treatment effects across frailty strata and reported consistent benefits, with potentially greater benefits in the highest frailty subgroup. However, frailty was not formally assessed in any of these trials, and the proxy measures used ma…
对本项目的价值
参考价值：属「衰弱 / 肌少症功能结局」方向；肌肉骨骼 / 衰弱 / 肌少症栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.0/5（★★☆☆☆）
全文不可及原因
标注 OA 但 PDF 下载失败或未通过题名指纹归属校验
原文题录
- 中文题名：衰弱评估与 CKD 疾病修饰治疗临床试验中的治疗效应
- 英文标题：Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD.
- 期刊与标识：Am J Kidney Dis · PMID 42966593 · DOI 10.1053/j.ajkd.2026.06.032 · EDAT 2026-10-31